SOURCE: Paragon Financial Limited

Paragon Financial Limited

June 01, 2012 08:20 ET

Plan to Speed Up FDA Reviews Recently Approved by Senate

The Paragon Report Provides Stock Research on AstraZeneca and GlaxoSmithKline

NEW YORK, NY--(Marketwire - Jun 1, 2012) - Lost revenues as a result of expiring patents have been a growing problem for the big pharmaceutical companies. New products that are being introduced into the market place are not expected to generate the same levels of revenues of top selling drugs that have lost patent protection. Drug manufacturers and medical device companies will look to get a boost as a $6.4 billion plan to speed up FDA reviews was recently approved by the Senate. The Paragon Report examines investing opportunities in the Drug Manufacturers Industry and provides equity research on AstraZeneca plc (NYSE: AZN) and GlaxoSmithKline plc (NYSE: GSK).

Access to the full company reports can be found at:

The bill, which the Senate voted 96-1, will raise the user fees the industries pay the FDA for reviews by $2 billion over the next five-year period. The House of Representatives could vote on the bill as early as next week. "This bill's passage is a victory for the millions of Americans who need medicines or medical devices and for the kind of cooperation that we see all too rarely in Washington," said Senators Tom Harkin, and Mike Enzi in a statement. The bill will "improve American families' access to lifesaving drugs and medical devices."

Paragon Report releases regular market updates on the Drug Manufacturers Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous stock reports and industry newsletters.

AstraZeneca is a global biopharmaceutical company. The company discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. The company previously reported that revenue for the first quarter was $7,349 million, down 11 percent at constant exchange rates.

GlaxoSmithKline is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The company earlier this month made an offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share in cash.

Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: